Paul Radspinner, MBA, president and CEO of FluGen, addresses the safety profile, noting the low adverse event rates highlighting the safety and tolerability of the H3N2 M2SR influenza vaccine.
Paul Radspinner, MBA
Advertisement
Paul Radspinner, MBA is the president and CEO of FluGen Inc.
Articles by Paul Radspinner, MBA
Advertisement
Latest Updated Articles
The Future of Influenza Vaccination: Insights from FluGen’s M2SR Vaccine StudyPublished: July 15th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
ViiV Healthcare Announces 96-Week PASO DOBLE Results Showing Dovato as Effective as Biktarvy in Maintaining Viral Suppression
2
Top Infectious Disease News Stories Week of October 11-October 17
3
